Tranexamic Acid: A Breakthrough in Aesthetic Dermatology

Once primarily utilized in surgical settings for its ability to control bleeding, Tranexamic Acid (TXA) is now emerging as a transformative ingredient in aesthetic dermatology.

A MEDICAL ORIGIN: FROM COAGULATION TO PIGMENTATION

Originally developed as a synthetic derivative of lysine, TXA has long been recognized for its antifibrinolytic properties. Interestingly, patients who received oral TXA for bleeding issues noted significant fading of melasma. Today, its topical application has positioned TXA as a leading solution for tackling hyperpigmentation and inflammation following cosmetic procedures.

THE POWER OF TXA AND NIACINAMIDE COMBINATION

The pairing of 5% Tranexamic Acid (TXA) with 10% Niacinamide has gained acclaim as one of the most effective combinations in the realm of aesthetic dermatology for addressing hyperpigmentation. TXA works by inhibiting tyrosinase and disrupting inflammatory and vascular responses, as well as the activation of melanocytes through the plasmin pathway. Meanwhile, Niacinamide plays a critical role in preventing melanin transfer to keratinocytes.

This synergy creates a robust dual-action approach to combat hyperpigmentation, developed by DERMEDEN Laboratories.

EFFECTIVENESS OF DERMEDEN MELAFLASH TXA+NIA

Clinical research has validated the safety and effectiveness of the DERMEDEN Laboratories MELAFLASH protocol, which includes 5% TXA and 10% Niacinamide. Various in vivo studies involving individuals with pigmentation issues such as melasma, solar lentigines, and post-inflammatory hyperpigmentation (PIH) have showcased its benefits. This solution is not only safe and effective but also easy to implement, with no restrictions on treatment frequency or duration, making it suitable for all Fitzpatrick skin types.